
Sign up to save your podcasts
Or


Business, when it’s at its best, can solve very big problems. And today Leadership Next is talking about a very big problem - COVID-19.
George Yancopoulos is the President and Chief Scientific Officer of Regeneron. His company announced this week it has developed a promising drug to fight coronavirus, and will begin human trials by early summer.
Yancopoulos details the innovative approach Regeneron used to create the drug - an approach that led to an effective therapy for Ebola.
He also explains that a Regeneron drug aimed at patients with rheumatoid arthritis is currently being used to treat some of the worst symptoms of COVID-19. The treatment is still in a trial phase but, if successful, could potentially keep severely ill patients off of ventilators.
Leadership Next host Alan Murray told Yancopoulos, “This is the most encouraging conversation I’ve had in quite awhile.”
By Fortune4.5
100100 ratings
Business, when it’s at its best, can solve very big problems. And today Leadership Next is talking about a very big problem - COVID-19.
George Yancopoulos is the President and Chief Scientific Officer of Regeneron. His company announced this week it has developed a promising drug to fight coronavirus, and will begin human trials by early summer.
Yancopoulos details the innovative approach Regeneron used to create the drug - an approach that led to an effective therapy for Ebola.
He also explains that a Regeneron drug aimed at patients with rheumatoid arthritis is currently being used to treat some of the worst symptoms of COVID-19. The treatment is still in a trial phase but, if successful, could potentially keep severely ill patients off of ventilators.
Leadership Next host Alan Murray told Yancopoulos, “This is the most encouraging conversation I’ve had in quite awhile.”

1,713 Listeners

4,420 Listeners

2,175 Listeners

1,993 Listeners

427 Listeners

2,672 Listeners

3,992 Listeners

582 Listeners

196 Listeners

167 Listeners

6,097 Listeners

1,573 Listeners

155 Listeners

187 Listeners

87 Listeners